Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic...
- Mechanism
- Curator reviewed
Fenretinide inhibits the growth of several human cancer cell lines, acting through both retinoid-receptor-dependent and retinoid-receptor-independent mechanisms.1In vivo, fenretinide selectively accumulates in breast tissue and is particularly active in inhibiting rat mammary carcinogenesis.1 An important feature of fenretinide is its ability to inhibit cell growth through the induction of apoptosis rather than through differentiation, an effect that is strikingly different from that of vitamin A.1 In contrast to tamoxifen, which inhibits only estrogen receptor (ER)-positive tumors, fenretinide induces apoptosis in both ER-positive and ER-negative breast cancer cell lines.2 All of these properties render fenretinide an attractive candidate for breast cancer chemoprevention.
- Primary indication
- Investigated for use/treatment in macular degeneration.Curator reviewed
- Formula / weight
- C26H33NO2 · 391.5457 g/mol (avg)
- Also known as
- 4-hydroxyphenyl retinamide
- Code names
- LAU-7b · MCN-R-1967
Resolves to
AKJHMTWEGVYYSE-FXILSDISSA-NSMILESC\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1What you can answer from here — as of July 03, 2026
Which drugs share a target with Fenretinide, and which of those have an active Phase 3 trial?